Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneerin

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-hu

The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and

New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with si

Editas narrows Q1 loss as costs fall, but revenues drop sharply. Pipeline focus shifts to in vivo ge

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and ra

Editas Medicine (EDIT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve e

Five abstracts have been accepted for presentation, including one oral presentation and two poster p

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should tak

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have received an average rating of

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the unde

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating

Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crus

Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and anno

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transf

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and rai

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises th

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a str

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, dem

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers th

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful R